NRSNW
NeuroSense Therapeutics Ltd. WarrantKey Statistics
About NeuroSense Therapeutics Ltd. Warrant
NeuroSense Therapeutics Ltd. is an innovative biotechnology firm focused on developing breakthrough therapies for neurodegenerative diseases, with a primary emphasis on amyotrophic lateral sclerosis (ALS). The company's lead therapeutic candidate targets critical mechanisms of disease progression, offering the potential for transformative treatment solutions. NeuroSense distinguishes itself through a multi-modal approach that combines various therapeutic strategies, positioning it uniquely within the competitive neurotherapeutics landscape. With a strong commitment to clinical development and scientific excellence, NeuroSense is well-positioned to make significant contributions to the biopharmaceutical sector and improve the quality of life for patients afflicted by serious neurological conditions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.07M |
| Operating Margin | 0.00% |
| Return on Equity | -2175.00% |
| Return on Assets | -247.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.05 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $23.34M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |